Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.
作者信息
Marti Catherine N, Fonarow Gregg C, Gheorghiade Mihai, Butler Javed
机构信息
Division of Cardiology, Emory University, Atlanta, GA.
出版信息
Circ Heart Fail. 2013 Sep 1;6(5):1095-101. doi: 10.1161/CIRCHEARTFAILURE.113.000518.
Abstract
摘要
相似文献
1
Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.针对住院心力衰竭患者的临床试验中干预措施的时间安排和持续时间。
Circ Heart Fail. 2013 Sep 1;6(5):1095-101. doi: 10.1161/CIRCHEARTFAILURE.113.000518.
2
Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.心力衰竭临床试验的惊人愚蠢：关于研究者和指南如何权衡证据的不便真相。
Circ Heart Fail. 2016 Apr;9(4):e002837. doi: 10.1161/CIRCHEARTFAILURE.116.002837.
3
Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations.在临床实践中，对慢性心力衰竭患者进行超过12个月的伊伐布雷定长期治疗：对症状、生活质量和住院情况的影响。
Int J Cardiol. 2017 Aug 1;240:258-264. doi: 10.1016/j.ijcard.2017.03.131. Epub 2017 Apr 11.
4
Heart failure: Heart failure clinical trials: how do we define success?心力衰竭：心力衰竭临床试验：我们如何定义成功？
Nat Rev Cardiol. 2013 Sep;10(9):492-4. doi: 10.1038/nrcardio.2013.115. Epub 2013 Aug 6.
5
Late In-Hospital Management of Patients Hospitalized with Acute Heart Failure.急性心力衰竭住院患者的院内晚期管理
Prog Cardiovasc Dis. 2017 Sep-Oct;60(2):198-204. doi: 10.1016/j.pcad.2017.05.003. Epub 2017 May 10.
6
Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial.参附注射液负荷量治疗冠心病慢性心力衰竭加重期患者的临床评估：一项随机对照试验的研究方案
Trials. 2015 May 21;16:222. doi: 10.1186/s13063-015-0729-7.
7
Guidelines for the diagnosis and management of heart failure.心力衰竭诊断和管理指南。
Am J Ther. 2004 Nov-Dec;11(6):467-72. doi: 10.1097/01.mjt.0000127150.21184.01.
8
Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.射血分数保留的心力衰竭试验的对照组存在异质性：Kaplan-Meier 曲线比较。
Cardiovasc Drugs Ther. 2018 Dec;32(6):577-580. doi: 10.1007/s10557-018-6827-5.
9
Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.生物标志物在心力衰竭临床试验中的既定作用与新兴作用
Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.115.002528.
10
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.全球心力衰竭住院患者临床试验中的试验点选择：存在问题及潜在解决方案。
Heart Fail Rev. 2014 Mar;19(2):135-52. doi: 10.1007/s10741-012-9361-8.
引用本文的文献
1
Myocardial Recovery in the Systemic Context: A Philosophic Shift for the Heart Failure Subspecialty to Optimize Patient Care.从整体角度看心肌恢复：心力衰竭亚专科优化患者治疗的哲学转变
Methodist Debakey Cardiovasc J. 2024 Aug 20;20(4):98-108. doi: 10.14797/mdcvj.1416. eCollection 2024.
2
Treatment Strategies of Improving Quality of Care in Patients With Heart Failure.改善心力衰竭患者护理质量的治疗策略
Korean Circ J. 2023 May;53(5):294-312. doi: 10.4070/kcj.2023.0024.
3
Comprehensive care for people living with heart failure and chronic obstructive pulmonary disease-Integration of palliative care with disease-specific care: From guidelines to practice.心力衰竭和慢性阻塞性肺疾病患者的综合护理——姑息治疗与疾病特异性护理的整合：从指南到实践
Front Cardiovasc Med. 2022 Sep 27;9:895495. doi: 10.3389/fcvm.2022.895495. eCollection 2022.
4
Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review.沙库巴曲缬沙坦：新的曙光已经来临！一篇重新回顾的综述。
Curr Cardiol Rev. 2022;18(3):e310821195982. doi: 10.2174/1573403X17666210831142452.
5
The Vulnerable Phase of Heart Failure.心力衰竭的易损期
Am J Ther. 2018 Jul/Aug;25(4):e456-e464. doi: 10.1097/MJT.0000000000000794.
6
Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey.医生对心力衰竭救命治疗指南建议的遵循质量：一项国际调查。
Card Fail Rev. 2017 Nov;3(2):130-133. doi: 10.15420/cfr.2017:13:1.
7
Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.背景和设计：TRANSITION 研究：随机比较出院前与出院后起始沙库巴曲缬沙坦治疗的研究。
ESC Heart Fail. 2018 Apr;5(2):327-336. doi: 10.1002/ehf2.12246. Epub 2017 Dec 14.
本文引用的文献
1
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.用于收缩性心力衰竭的新型蛋白类治疗药物：慢性皮下注射 B 型利钠肽。
J Am Coll Cardiol. 2012 Dec 4;60(22):2305-12. doi: 10.1016/j.jacc.2012.07.056. Epub 2012 Nov 1.
2
Ethnic differences in 1-year mortality among patients hospitalised with heart failure.心力衰竭住院患者 1 年死亡率的种族差异。
Heart. 2011 Jul;97(13):1048-53. doi: 10.1136/hrt.2010.217869. Epub 2011 Apr 20.
3
Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial.植入式胸腔内阻抗监测对心力衰竭住院预测的敏感性和阳性预测值：SENSE-HF 试验。
Eur Heart J. 2011 Sep;32(18):2266-73. doi: 10.1093/eurheartj/ehr050. Epub 2011 Feb 28.
4
Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase.急性心力衰竭综合征药物治疗的临床研究进展：提出一种机制转化阶段的建议。
Am Heart J. 2011 Feb;161(2):224-32. doi: 10.1016/j.ahj.2010.10.023. Epub 2010 Dec 28.
5
β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure.β-痕迹蛋白和胱抑素 C 可预测急性心力衰竭患者的长期预后。
J Am Coll Cardiol. 2011 Feb 15;57(7):849-58. doi: 10.1016/j.jacc.2010.08.644.
6
Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis.尿酸作为心力衰竭全因死亡率的预测指标：一项荟萃分析。
Congest Heart Fail. 2011 Jan-Feb;17(1):25-30. doi: 10.1111/j.1751-7133.2011.00200.x. Epub 2011 Jan 27.
7
Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure.基质金属蛋白酶（MMP）-2在急性心力衰竭患者中的临床意义
Int Heart J. 2010;51(6):404-10. doi: 10.1536/ihj.51.404.
8
Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).多中心、随机、双盲、安慰剂对照的阿利克仑急性心力衰竭结局试验（ASTRONAUT）的原理和设计。
Eur J Heart Fail. 2011 Jan;13(1):100-6. doi: 10.1093/eurjhf/hfq209. Epub 2010 Nov 30.
9
Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).改善门诊心脏病学实践中心力衰竭的循证护理：改善门诊心力衰竭证据治疗应用注册研究（IMPROVE HF）的主要结果。
Circulation. 2010 Aug 10;122(6):585-96. doi: 10.1161/CIRCULATIONAHA.109.934471. Epub 2010 Jul 26.
10
Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure.医生指导的慢性心力衰竭晚期患者左心房压力的自我管理。
Circulation. 2010 Mar 9;121(9):1086-95. doi: 10.1161/CIRCULATIONAHA.108.800490. Epub 2010 Feb 22.
Zotero 插件